GERMANTOWN, Md., Oct. 30 /PRNewswire-FirstCall/ -- MiddleBrook Pharmaceuticals, Inc. , a pharmaceutical company focused on developing and commercializing novel anti-infective products, is scheduled to announce its financial results for the third quarter of 2008 on Thursday, Nov. 13, 2008, before the market opens. At 9:00 a.m. (ET) on that day, MiddleBrook management will conduct a conference call to review the Company's third quarter financial results.
To listen live to the call, dial 1-800-813-8504 or 1-706-643-7752. A replay of the call will be available starting at approximately 11 a.m. on Nov. 13 through 5 p.m. on Nov. 20, 2008. To listen to the replay, dial 1-800-642-1687 or 1-706-645-9291 and enter the conference ID # 71538195.
A live audio webcast of the conference call also will be available by going to the Investor Relations section of MiddleBrook's web site, www.middlebrookpharma.com. A replay of the webcast will be available starting at approximately 11 a.m. on Nov. 13 through 5 p.m. on Dec. 12, 2008.
About Middlebrook Pharmaceuticals:
MiddleBrook Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of anti-infective drug products that fulfill substantial unmet medical needs in the treatment of infectious disease. The Company is developing anti-infective drugs based on its novel biological finding that bacteria exposed to antibiotics in pulses are killed more efficiently than those under standard treatment regimens. Based on this finding, MiddleBrook has developed a proprietary, once-a-day pulsatile delivery technology called PULSYS(R). The Company currently markets the KEFLEX(R) brand of cephalexin and has received regulatory approval for MOXATAG(TM) - the first and only once-daily amoxicillin product approved for marketing in the U.S. For more information about MiddleBrook, please visit www.middlebrookpharma.com.
CONTACT: Faith Pomeroy-Ward +1-301-944-6585
Web site: www.middlebrookpharma.com/
